{"entity":{"id":"cd70","kind":"target","name":"CD70","aka":[],"tldr":"CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.","summary":"CD70 is the TNF-family ligand for CD27, normally expressed only transiently on activated immune cells, but permanently switched on in clear-cell RCC and a range of haematologic malignancies with minimal normal expression. It is found in 80-90% of clear-cell RCC by IHC and on blasts and leukaemic stem cells in 30-50% of AML, as well as in lymphomas. Allogeneic CD70 CAR-T (ALLO-316) has shown responses in RCC, a notable result because solid tumours have resisted CAR-T. An advantage of the target is that CD70-directed cells may also deplete alloreactive host T cells, which helps off-the-shelf products persist. Durability of response and safety in AML are open. The simple version is an immune-cell protein that kidney cancer keeps switched on, offering a target for donor-derived CAR-T.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/CD70","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/CD70"}],"tags":["car-t-target"],"related":[],"cancers":["rcc","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cusatuzumab","adi-270"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"CD70","role":[],"sources":[],"specificity":"lineage-antigen","distribution":"few-types","specificityNote":"Lineage antigen shared with normal T-cells and lymphoid tissue cells: HPA blood lineage group enriched at or above 25 nTPM, and 1 cell-killing or cell-finding medicine (ADI-270) aim at it, so normal cells of the lineage are hit too. HPA CD70: RNA tissue enhanced (lymphoid tissue 3 nTPM); blood lineage group enriched (B-cells 24 nTPM, T-cells 44 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CD70 tissue","url":"https://www.proteinatlas.org/ENSG00000125726-CD70/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CD70 pathology","url":"https://www.proteinatlas.org/ENSG00000125726-CD70/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000125726 associations","url":"https://platform.opentargets.org/target/ENSG00000125726/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:11937","ensembl":"ENSG00000125726","uniprot":"P32970","entrez":"970","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Goodwin R.G. et al, Cell, 1993, \"Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8387892/","biology":"CD70 is the TNF-family ligand for CD27.","whereFound":["Clear-cell RCC","AML","Lymphomas"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"rcc","pct":"80-90","measure":"Clear-cell, IHC","source":"https://en.wikipedia.org/wiki/CD70"},{"cancerId":"aml","pct":"30-50","measure":"Blasts and leukaemic stem cells","source":"https://en.wikipedia.org/wiki/CD70"}]},"route":"/targets/cd70/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/"},{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"company":[{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/"}],"target":[{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/"}]}}